See the DrugPatentWatch profile for Cymbalta
What are the key differences between Cymbalta and amitriptyline?
Cymbalta (duloxetine) and amitriptyline are used for overlapping pain conditions, but they work differently. Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI). Amitriptyline is a tricyclic antidepressant (TCA). That means the side-effect patterns and safety tradeoffs tend to differ, especially for sedation, weight gain, heart rhythm effects, and withdrawal/taper needs.
Which one is typically chosen for nerve pain (neuropathic pain) or chronic pain?
Both drugs are used when pain is tied to nerve signaling, but Cymbalta is commonly selected for neuropathic pain and conditions like fibromyalgia and chronic musculoskeletal pain because it is an SNRI with pain-modulating effects. Amitriptyline is also used for neuropathic pain and chronic pain, and it’s often taken at night when sedation is helpful.
Choice often depends on the patient’s symptom pattern and risk factors:
- If daytime alertness matters, Cymbalta may be preferred over amitriptyline for many people because amitriptyline is more likely to cause drowsiness.
- If sleep is a problem and a clinician wants to use nighttime dosing, amitriptyline may fit better.
How do side effects compare?
Common practical differences patients notice include:
- Sedation and drowsiness: Amitriptyline is more likely to cause significant drowsiness, especially early in treatment or after dose increases. Cymbalta can cause fatigue, but sedation tends to be less pronounced than with TCAs for many patients.
- Anticholinergic effects: Amitriptyline can cause dry mouth, constipation, urinary retention, and blurred vision more often than Cymbalta because of its TCA activity.
- Weight and metabolic effects: Amitriptyline is more associated with weight gain than SNRIs for many patients.
- Blood pressure and nausea: Cymbalta more often causes nausea and can affect blood pressure (clinicians monitor this). Amitriptyline can also cause nausea but is typically discussed more for sedation/anticholinergic effects.
- Heart rhythm risk: TCAs like amitriptyline can affect cardiac conduction and may be riskier in people with certain heart conditions or in overdose scenarios. Cymbalta has different cardiovascular considerations, generally not the same conduction risks as TCAs.
If you have glaucoma, prostate/bladder emptying issues, significant constipation, or a history of arrhythmia, those factors often steer clinicians away from amitriptyline.
What about antidepressant overlap—can they be used for depression too?
Yes. Cymbalta is an antidepressant (with pain indications). Amitriptyline is also an antidepressant. In practice, pain patients who also have depression or anxiety may still get either option depending on tolerability and safety.
How hard is it to stop—do they both require tapering?
Both drugs can cause discontinuation symptoms if stopped abruptly, so clinicians typically recommend tapering. The specific pattern differs by drug and dose, but the general principle is to avoid sudden stopping.
Can they be combined or switched?
Combining Cymbalta and amitriptyline is sometimes considered by clinicians, but it increases the risk of side effects and drug-interaction concerns (including serotonin-related effects and additive adverse effects). Switching between them also needs a plan to reduce withdrawal symptoms and avoid overlap risk.
If you’re moving from one to the other, the safest approach is clinician-guided tapering and timing rather than self-switching.
Which has a faster onset for pain?
Both can take time to show full pain benefit. Many patients notice some change within the first couple of weeks, with more gradual improvement over subsequent weeks. The dosing schedule and whether you’re using it for neuropathic pain versus depression can affect the timeline.
Safety edge cases: when should you be extra cautious?
Amitriptyline generally needs more caution in situations such as:
- Heart rhythm problems or conduction abnormalities
- Higher risk of falls/sedation (especially in older adults)
- Significant constipation or urinary retention risk
- Overdose risk (TCAs can be more dangerous in overdose)
Cymbalta generally needs more caution regarding:
- Liver disease (it can be harder on the liver)
- Uncontrolled hypertension (clinicians monitor blood pressure)
- Higher risk of nausea or treatment-emergent side effects at dose starts
Sources
No sources were provided with your question, so I can’t cite DrugPatentWatch.com or other references here. If you want, tell me your goal (neuropathy, fibromyalgia, depression, sleep, etc.) and your age/major medical conditions, and I’ll tailor a direct Cymbalta vs amitriptyline comparison to what matters most for your situation.